Dr. Reddy's Laboratories announces the launch of Albendazole Tablets, USP in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Albendazole Tablets, USP, a therapeutic equivalent generic version of Albenza Tablets, 200 mg, approved by the U.S. Food and Drug Administration (USFDA).

The Albenza brand and generic had U.S. sales of approximately $27 million MAT for the most recent twelve months ending in November 2020 according to IQVIA Health*.

Dr. Reddy's Albendazole Tablets, USP are available in 200 mg tablets in bottle count sizes of two.

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.5101.35 as compared to the previous close of Rs. 5043.4. The total number of shares traded during the day was 49981 in over 5016 trades.

The stock hit an intraday high of Rs. 5144.25 and intraday low of 5043. The net turnover during the day was Rs. 254841464.

Albenza is a trademark of Glaxosmithkline

Source : Equity Bulls

Keywords